Skip to main content
. 2017 Oct 17;50(3):956–963. doi: 10.4143/crt.2017.181

Fig. 1.

Fig. 1.

Comparison of progression-free survival in patients relative to the tumorigenicity of engrafted tumors in a xenograft model. (A) Comparison in 88 patients. (B) Subgroup analysis by type of debulking surgery: primary and interval debulking. PDS, primary debulking surgery; IDS, interval debulking surgery.